Biocodex is an independent, multinational pharmaceutical company founded in France in 1953. Its original focus was on gastroenterology, specifically the use of a unique yeast, Saccharomyces boulardii CNCM I-745®, the primary ingredient in the first probiotic of its kind. The yeast proved to have a positive effect on intestinal microbiota and on certain pathological side effects caused by an imbalance in microbiota (dysbiosis), including antibiotic-associated diarrhea, intestinal infections of C. difficile, and acute gastroenteritis. Today, Biocodex has grown and expanded its focus, research, and expertise into microbiota and probiotics.


There is growing interest in microbiota because of its implication in a wide variety of illnesses. A better understanding of microbiotic composition through the use of metagenomic approaches, along with an enhanced knowledge of its role, mean that modulating the microbiota as part of the treatment of illnesses in which it may be an indicator can be envisaged. But there is still a great deal of work to be done, in particular to evaluate how microbiota interact with the body as a whole through neural and humoral pathways.

Biocodex Microbiota Foundation

The Biocodex Microbiota Foundation’s mission is to promote research into microbiota and their interaction with various pathologies. Research is supported through grants given to projects that investigate the implication of microbiota in human health. BMF supports both foundational and applied research. Projects are selected annually by a committee of independent international scientists.

Mission and Methods

The BMF’s primary activity is the awarding of annual grants to innovative scientific research projects that explore the structure of microbiota and, in particular, the impact of an imbalance in microbiota, known as dysbiosis, on the occurrence or evolution of various pathologies.

These grants help further both fundamental and applied research. They are available in a number of countries (“national grants”) and are awarded by national juries. One particularly significant international grant is awarded by a committee of independent international scientists.

The BMF also runs and helps establish programs to improve our understanding of microbiota and disseminates this knowledge as widely as possible by organizing scientific meetings dedicated to microbiota and by setting up training sessions. Finally, the BMF can establish public projects which aim to help improve human health and which involve microbiota.

Our values

Biocodex Microbiota Foundation, created by Biocodex Laboratories, bases its mindset and vision of the future on the following values:


Trust in the scientific community, which guarantees that Biocodex Microbiota Foundation’s ambition is built exclusively on the authority of knowledge;


Respect for its own rhythm and culture, in order to encourage the emergence of fruitful products;


Humility given the size of the task. Responsibility is not a matter of making short-term commitments, but rather of seeking to pursue potentially productive initiatives. The Foundation is here for the long term, the only way in which what is of secondary interest can be abandoned in favor of what is fundamental and significant;


Perseverance, therefore, because the Foundation is here for the long term, with no concerns about profitability, regardless of the outcome of research. Its mission, based on the study of the latest scientific problems and respect for the pace of research, is a patient commitment and is inseparable from confidence about decisive future discoveries.


Marie Emmanuelle Le Guern

Vice President Research and Development Biocodex Laboratory Compiègne, France.

Murielle Escalmel

Global Microbiota Communication Director Biocodex Laboratory Gentilly, France

Maxime Prost à la Denise

Medical Affairs Director, France Division Biocodex Laboratory Gentilly, France

Lynne Mc Farland

Department of Health Services Research and Development, VA Hospital – Houston, USA

Aude Boclé

General Manager Biocodex Mexico

Xavier Roux

Head of Microbiology Department Biocodex Laboratory Compiègne, France

Alain Marié

Vice President of the Health Professionals Group Medical Director Quotidien du Médecin, Malakoff, France

Harry Sokol

Gastroenterology Professor, Department of Gastroenterology, Saint-Antoine Hospital – Paris, France

International scientific committee

Harry Sokol

President (F)

Gastroenterology Professor, Department of Gastroenterology, Saint-Antoine Hospital – Paris, France

Joel Doré


Research and Scientific Director of the MetaGenoPolis service unit (INRA) – Jouy en Josas

Francisco Guarner


Research Unit on digestive systems, Val d’Hebron Hospital, Barcelona

C. Högenauer


Division of Gastroenterology and Hepatology, Medical University of Graz

Magnus Simrén


Professor of Gastroenterology, University of Gothenburg - Sweden

N. Segata


Head of the Laboratory of Computational Metagenomic, Center for Integrative Biology, University of Trento

E. Verdu


Professor at the division of Gastroenterology, Dep. Of Medicine, McMaster University - Hamilton

G. Wu


Gastroenterology, Ferdinand G Weisbrod Professor PennCHOP Microbiome Program Perelman, University of Pennsylvania - Philadelphie